Maggie Larché @CSRG2022

We’re excited to announce the relaunch of the Canadian Scleroderma Research Group (CSRG) — now redesigned with a new protocol and several important updates. Whether you’re joining for the first time or returning as an active site, we look forward to having your team on board.

keyboard_arrow_left Previous keyboard_arrow_right Next

Suicide prevention is part of whole-patient care. On World Suicide Prevention Day, how do you open space for mental health in your systemic sclerosis practice?

keyboard_arrow_left Previous keyboard_arrow_right Next

⏰ It’s National Be Late for Something Day — but don’t be late in spotting the early signs of systemic sclerosis (SSc). Early detection = better outcomes. 💙

keyboard_arrow_left Previous keyboard_arrow_right Next

👋 The CSRG team wants to hear from YOU—our colleagues in rheumatology, medicine, and pharma! We’re looking for your ideas on what you’d like to see featured on our social media channels.

At CSRG we are turning hard facts into groundbreaking insights — our biobank is where tough samples meet cutting-edge science.

📢 CSRG has Reached 100+ Publications on Scleroderma 📢 We’re proud to share that the Canadian Scleroderma Research Group (CSRG) has published over 100 peer-reviewed research papers focused on scleroderma.

keyboard_arrow_left Previous keyboard_arrow_right Next

📊 What is CSRG? Canadian Scleroderma Research Group (CSRG) is a national, multi-center research initiative dedicated to improving the lives of people living with SSc. Through cuttingedge research and collaboration, we’re helping to uncover new insights into this complex disease.

June 29 - World Scleroderma Day: CSRG is thankful for all the patients who share their time by participating in research studies.

See this Instagram video by @SclerodermaCAN instagram.com/reel/DLQV1QEPl…

CSRG is set to Make a Move across Canada! Find your local event this weekend and have some fun while raising funds :)

💊 Immunosuppression in early SSc—a growing trend? New data shows a rise in early treatment. Is the field shifting toward earlier intervention to change long-term outcomes?

keyboard_arrow_left Previous keyboard_arrow_right Next

CSRG is proudly funded partially by Scleroderma Canada! Come Make A Move with us as we raise essential funds for research. Find a walk near you!

Clinicians — how often do you ask about work when seeing your patients with systemic sclerosis? 🩺💼 This 2009 article by Hudson et al. found that nearly half of SSc patients were work-disabled early in their disease course. 👉 jrheum.org/content/36/11/…

keyboard_arrow_left Previous keyboard_arrow_right Next

🔬 Research Highlight from CSRG! Can simple blood tests help predict serious heart and lung complications in systemic sclerosis? Read more about how this could change early detection and care. 👇 pmc.ncbi.nlm.nih.gov/articles/PMC89…

keyboard_arrow_left Previous keyboard_arrow_right Next

Celebrating Volunteer Week at CSRG! This week, we're proud to celebrate Volunteer Week, a time to recognize and thank the incredible individuals who contribute their time and skills to help our community thrive.

keyboard_arrow_left Previous keyboard_arrow_right Next

📰 Article Highlight Check out this fascinating new research exploring patterns of disease progression in systemic sclerosis. Using a unique modeling approach, the study offers fresh insights into how damage unfolds over time.

keyboard_arrow_left Previous keyboard_arrow_right Next

🫁 CSRG Research Feature Interstitial Lung Disease (ILD) is a serious complication in systemic sclerosis. CSRG research is helping us better understand its impact and improve outcomes for people living with this condition.

keyboard_arrow_left Previous keyboard_arrow_right Next

Article Highlight: CSRG and Australian Scleroderma Interest Group explores how immunosuppressive drugs (ISs) impact damage accrual in early systemic sclerosis (SSc). 📷 Key Findings: Limited cutaneous SSc (lcSSc) – ISs were linked to lower organ damage.

keyboard_arrow_left Previous keyboard_arrow_right Next

Article highlight: A recent study from our registry explores the link between autoantibodies in systemic sclerosis (SSc) and an increased risk of cancer.

keyboard_arrow_left Previous keyboard_arrow_right Next

🚨 CSRG at CRA 2025! 🚨 We had an incredible time networking, learning, and collaborating with rheumatology professionals, researchers, and industry partners. Here are some key highlights from the conference! ⬇️

keyboard_arrow_left Previous keyboard_arrow_right Next